| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_5927143d3f95c5fb26d1d20d00099031 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P11-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-352
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-496
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A23L33-10 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P11-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-496
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A23L33-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-352
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 |
| filingDate |
2022-04-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_23cbfe20cdb6a6b2872f8b7140ad2550
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9a12ed014492b21939e74b35890c27c3
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d8cd01ee9aee6dfd938e97fca9620320
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2bab90b226af38024f8b44f2e10a7631
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_461d1d71c2bfd8eb357f8086428fe71d |
| publicationDate |
2022-10-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-2022225259-A1 |
| titleOfInvention |
Anticancer composition inducing cell senescence and cell death |
| abstract |
The present invention relates to an anticancer composition containing as an active ingredient a compound inducing cell senescence and cell death. The compound of the present invention can discriminate cancer cells and normal cells and induce both cell senescence and cell death in a cancer cell-specific manner. Thus, the compound does not need the attachment of any cancer cell-specific targeting substance thereto, can minimize the frequent adverse effects caused by the attack of anticancer agents on normal cells, and exhibits a potent anticancer effect on the basis of the aforementioned dual action. |
| priorityDate |
2021-04-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |